Clavispora (Candida) lusitaniae susceptibility profiles and genetic diversity in three tertiary hospitals (1998–2001)

Kollia, Kalomoira; Arabatzis, Michael; Kostoula, Olga; Kostourou, A.; Velegraki, Aristea; Belessiotou, Elina; Lazou, Aekaterini

doi:10.1016/s0924-8579(03)00161-4

Cited by 10 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the susceptible dose dependent MIC readings (21) for itraconazole (0.125–0.5 μg/ml), all patients with mucosal lesions caused by such strains responded to 15 days' itraconazole treatment (200 mg/day). A similar itraconazole therapeutic outcome has been noted before in a cancer patient with Candida lusitaniae vaginal infection (16). Correlation of in vitro susceptibility test results and in vivo outcome has been substantiated using a murine model of invasive candidiasis in relation to fluconazole treatment (2).…”

Section: Discussionsupporting

confidence: 76%

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment

Belazi

Velegraki

Koussidou-Eremondi

et al. 2004

Oral Microbiology and Immunology

View full text Add to dashboard Cite

Oral pseudomembranous candidiasis and mucositis were assessed in 39 patients receiving a total dose of 39-70 Gy radiotherapy for head and neck cancer. Mucositis was scored using the Radiation Therapy Oncology Group criteria, and oral candidiasis was diagnosed on the basis of clinical evaluation and quantitative laboratory findings. Radiation-induced mucositis was observed in 9/39 patients. Only 3/39 patients discontinued radiotherapy due to acute severe mucosal effects. Candidiasis (colony-forming units 35 to > or = 60/lesion) associated with mucositis was diagnosed in 30/39 patients: the most frequent aetiology of the infection was Candida albicans (n = 23), followed by Candida glabrata (n = 3), Candida krusei (n = 2), Candida tropicalis (n = 1) and Candida kefyr (n = 1). Patients with confirmed oral pseudomembranous candidiasis were treated with either fluconazole 200 mg/day or itraconazole 200 mg/day for 2 weeks. Clinical improvement and concomitant negative Candida cultures (mycologic cure) were the criteria determining a response to antifungal treatment. Etest revealed very low voriconazole MICs (0.004-0.125 microg/ml) for all isolates, and fluconazole resistance for eight C. albicans strains (MIC > 64 microg/ml) and for the C. krusei isolates (MIC > 32 microg/ml). The same strains showed itraconazole susceptibility dose dependence (MIC 0.5 microg/ml). Despite the itraconazole susceptible dose dependent MIC readings, all patients with oral pseudomembranous candidiasis caused by these strains responded to antifungal treatment with 200 mg/day itraconazole. Oral mycologic surveillance of patients undergoing radiotherapy for head and neck malignancies and susceptibility testing of isolates may be indicated in cases with mucositis-associated confirmed oral pseudomembranous candidiasis to ensure prompt administration of targeted antifungal treatment. On the basis of the low MIC values found, clinical evaluation of voriconazole is indicated for management of oral pseudomembranous candidiasis refractory to other azoles.

show abstract

Section: Discussionsupporting

confidence: 76%

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment

Belazi

Velegraki

Koussidou-Eremondi

et al. 2004

Oral Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Yeasts were identified using standard procedures. Susceptibility to antifungals of five different colonies from each isolate was determined by Etest (AB Biodisk, Solna, Sweden), as described before [8].…”

Section: Oral Clinical Evaluationmentioning

confidence: 99%

Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy

Nicolatou‐Galitis

Velegraki

Sotiropoulou-Lontou

et al. 2005

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Peyron et al (8) suggested to the E test as the most sensitive and reliable means of detecting AMB resistance. Kollia et al (9) reported MIC range of antifungal agents with the method of E test against 12 C. lusitaniae strains and the MIC range of AMB and fluconazole were 0.01-0.125, 0.75->64, respectively. Blinkhorn et al (7) reported MIC for AMB of 2 C. lusitaniae strains isolated in blood and for the C. lusitaniae strain isolated from their patients, the MIC of AMB was 0.39 μg/ ml.…”

Section: Discussionmentioning

confidence: 99%

Candida Utilis and Candida Lusitaniae Meningitis in an Infant with Extraventricular Drainage

Sariguzel¹,

Koç²,

Öztürk³

2017

Van Med J

View full text Add to dashboard Cite

Clavispora (Candida) lusitaniae susceptibility profiles and genetic diversity in three tertiary hospitals (1998–2001)

Cited by 10 publications

References 9 publications

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment

Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment

Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy

Candida Utilis and Candida Lusitaniae Meningitis in an Infant with Extraventricular Drainage

Contact Info

Product

Resources

About